Improving long-term renal allograft survival via a road less traveled by

American Journal of Transplantation

Volumn 11, Issue 7, 2011, Pages 1382-1387

  Stegall, M D ^a   Park, W D ^a   Dean, P G ^a   Cosio, F G ^b  

^a William J von Liebig Transplant Center   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Allograft nephropathy; chronic rejection; immunosuppressive therapy; kidney transplantation; long term graft survival

Indexed keywords

ALLOANTIBODY; CALCINEURIN INHIBITOR; CYCLOSPORIN; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; CELL INFILTRATION; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; POLYOMA VIRUS; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79959852367     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03557.x     Document Type: Review

References (26)

1. Ferguson R,. Acute rejection episodes-best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328-331. (Pubitemid 24163500)
2. Tantravahi JR, Womer KL, Kaplan B,. Why hasn't eliminating acute rejection improved graft survival? Ann Rev Med 2007; 58: 369-385. (Pubitemid 46706521)
3. Lamb KE, Lodhi S, Meier-Kriesche H-U,. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450-462.
4. Kasiske BL, Kalil RS, Lee HS, Rao KV,. Histopathologic findings associated with chronic, progressive decline in renal allograft function. Kidney Int 1991; 40: 514-524.
5. Humar A, Kerr S, Gillingham KJ,. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200-1203. (Pubitemid 29517713)
6. Nankivell BJ, Borrows RJ, Fung C L-S, O'Connell PJ, Allean RDM, Chapman JR,. The natural history of chronic allograft nephropathy. N Eng J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
7. Stegall MD, Park WD, Larson TS, et al,. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698-707.
8. El-Zoghby ZM, Stegall MD, Lager DJ, et al,. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
9. Isssa N, Cosio FG, Gloor JM, et al,. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 15: 681-685.
10. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD,. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987-1997.
11. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RWG,. Post-transplant production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation. 2003; 75: 1034-1040. (Pubitemid 36438534)
12. Lee P-C, Terasaki PI, Takemoto SK, et al,. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2003; 74: 1192-1194. (Pubitemid 35216119)
13. Gaston RS, Cecka JM, Kasiske BL, et al,. Evidence for antibody-mediated injury as a major determinant of late kidney graft failure. Transplantation 2010; 90: 68-74.
14. Kawai T, Cosimi AB, Spikzer TR, et al,. HLA-mismatched renal transplantation without maintenance immunosuppression. N Eng J Med 2008; 358: 353-361. (Pubitemid 351159234)
15. Knechtle SJ, Pascual J, Bloom DD,. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring. Am J Transplant 2009; 9: 1087-1098.
16. Dean PG, Grande JP, Sethi S, et al,. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212-1215. (Pubitemid 351590201)
17. Pearson T,. An MMF based regimen in combination with sirolimus after CNI withdrawal in renal transplant recipients: Final results of the Spare the Nephron Trial. American Transplant Congress June 1, 2008.
18. Vicenti F, Chapentier B, Vanrenterghem Y, et al,. A phase III study of bleatacept-based immunosuppression regiments versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
19. Busque S, Leventhal J, Brennan DC, et al,. Calcineurin-inhibitor free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936-45
20. Gaston RS,. Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm. Clin J Am Soc Neprhol 2009; 4: 2029-2034.
21. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
22. Trivedi HL, Terasaki PI, Feroz A, et al,. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
23. Porrini E, Delgado P, Bigo C, et al,. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006; 48: 134-142.
24. Schwarz A, Gwinner W, Hiss M, Radermacher J, Mengel M, Haller H,. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 5: 1992-1996. (Pubitemid 41039876)
25. Wilkinson A,. Protocol transplant biopsies: Are they really needed? Clin J Am Soc Nephrol 2006; 1: 130-137.
26. Hirsch HH, Brennan DC, Crachenberg CB, et al,. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277-1286. (Pubitemid 40734783)